Kingsview Wealth Management LLC Makes New $1.77 Million Investment in DexCom, Inc. (NASDAQ:DXCM)

Kingsview Wealth Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 14,267 shares of the medical device company's stock, valued at approximately $1,770,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Valley National Advisers Inc. lifted its position in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company's stock worth $30,000 after purchasing an additional 103 shares in the last quarter. MV Capital Management Inc. increased its stake in DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company's stock valued at $34,000 after buying an additional 138 shares during the last quarter. Smithfield Trust Co lifted its position in DexCom by 103.1% during the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company's stock worth $40,000 after buying an additional 165 shares in the last quarter. Washington Trust Advisors Inc. boosted its stake in shares of DexCom by 120.6% during the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company's stock worth $44,000 after buying an additional 193 shares during the last quarter. Finally, NBC Securities Inc. bought a new position in shares of DexCom in the 3rd quarter valued at about $47,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 629 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the sale, the executive vice president now owns 68,212 shares in the company, valued at approximately $8,611,765. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Michael Jon Brown sold 629 shares of the firm's stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the sale, the executive vice president now directly owns 68,212 shares of the company's stock, valued at $8,611,765. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sadie Stern sold 4,137 shares of the business's stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $140.00, for a total value of $579,180.00. Following the transaction, the executive vice president now directly owns 76,304 shares of the company's stock, valued at approximately $10,682,560. The disclosure for this sale can be found here. Insiders sold a total of 190,004 shares of company stock valued at $25,610,270 over the last quarter. 0.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DXCM. Raymond James increased their price target on DexCom from $151.00 to $160.00 and gave the company a "strong-buy" rating in a research report on Friday, April 26th. Royal Bank of Canada assumed coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an "outperform" rating and a $165.00 price target on the stock. StockNews.com upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research note on Friday. Citigroup upped their target price on shares of DexCom from $148.00 to $161.00 and gave the company a "buy" rating in a report on Wednesday, April 3rd. Finally, UBS Group boosted their price target on DexCom from $153.00 to $163.00 and gave the stock a "buy" rating in a research report on Wednesday, April 10th. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $141.67.

DexCom Stock Performance

DexCom stock traded down $0.55 during midday trading on Friday, hitting $131.36. The company's stock had a trading volume of 2,329,399 shares, compared to its average volume of 2,690,321. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The company has a market cap of $52.24 billion, a price-to-earnings ratio of 84.75, a PEG ratio of 2.25 and a beta of 1.23. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The company has a 50-day moving average price of $133.26 and a two-hundred day moving average price of $123.00.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.05. The business had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, sell-side analysts predict that DexCom, Inc. will post 1.78 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.